Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Office of AIDS Research (OAR)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

 Applicants should carefully note which ICOs participate in this announcement and refer to NIH Institute, Center, and Office Grants & Funding Profiles for ICO-specific missions, interest areas, priorities, and funding considerations.

Funding Opportunity Title

HIV/AIDS Clinical Trials Network Leadership and Operations Centers (UM1 Clinical Trial Required)

Activity Code

UM1 Research Project with Complex Structure Cooperative Agreement

Announcement Type

Reissue of RFA-AI-19-003
Reissue of RFA-AI-19-004
Reissue of RFA-AI-19-005
Reissue of RFA-AI-19-006

Related Notices

Funding Opportunity Number (FON)

RFA-AI-28-001

Companion Funding Opportunity

RFA-AI-28-002 , UM1 Research Project with Complex Structure Cooperative Agreement
RFA-AI-28-003 , UM1 Research Project with Complex Structure Cooperative Agreement
RFA-AI-28-004 , UM1 Research Project with Complex Structure Cooperative Agreement

Number of Applications

See Part 2, Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.8RP, 93.DE1, 93.HDR, 93.AGR, 93.242, 93.310, 93.853, 93.DA1, 93.HL2, 93.KRC

Funding Opportunity Purpose

The purpose of this notice of funding opportunity (NOFO) is to support HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs). Each LOC will oversee research prioritization, planning, and conduct of studies in a HIV/AIDS Clinical Trials Network to advance research in the prevention and treatment of HIV and HIV-associated diseases. 

Funding Opportunity Goal(s)

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

Key Dates

Posted Date

November 20, 2026

Open Date (Earliest Submission Date)

February 09, 2027
Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed Scientific Merit Review Advisory Council Review Earliest Start Date
March 09, 2027 March 09, 2027 Not Applicable July 2027 October 2027 December 2027

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

March 10, 2027

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Network Scope and Structure

The National Institute of Allergy and Infectious Diseases (NIAID) and its Institute, Center, and Office (ICO) partners will support four clinical trials networks with unique research agendas that will conduct HIV/AIDS prevention, treatment and implementation science research, improving uptake of evidence-based strategies across the lifespan: 

  1. HIV/AIDS Adult Therapeutics Clinical Trials Network 

  2. HIV/AIDS Maternal, Adolescent and Pediatric Clinical Trials Network 

  3. HIV Prevention Clinical Trials Network 

  4. Immune-Based Prevention Clinical Trials Network 

 Each HIV/AIDS Clinical Trial Network is composed collectively of the following clinical trial infrastructure designed to support a complex clinical research agenda: 

RFA-AI-28-001 - HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs) – this notice of funding opportunity (NOFO)
RFA-AI-28-002 - HIV/AIDS Clinical Trials Network Laboratory Centers (LCs)
RFA-AI-28-003 - HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (SDMCs)
RFA-AI-28-004 - HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs)

While the emphasis of each Network is on clinical trials, clinical research studies that are not NIH-defined clinical trials are also in scope when undertaken to support the program. For this NOFO, the term "clinical study" refers to both clinical trials and clinical research studies, and "clinical trial" is used to refer to a clinical trial only. 

NIAID plans to fund one LOC award for each Network, with one LOC per research agenda described below.  

Each Clinical Trials Network will have an Executive Management Committee (EMC), established by the LOC, to coordinate the activities of the Network's LOC, LC and SDMC.  

NIAID is responsible for the oversight and safety of all study participants in clinical trials funded by NIAID and will provide NIAID-convened Data and Safety Monitoring Boards (DSMBs) to monitor clinical trials. NIAID will provide additional support services for Network trials under an Investigational New Drug (IND) or Investigational Device Exemption (IDE).  

Leadership and Operations Center Specific Responsibilities

Each LOC will oversee one research agenda and will be responsible for the prioritization, planning, and conduct of studies in a HIV/AIDS Clinical Trials Network. The Networks will conduct studies to evaluate innovative strategies, as well as conduct implementation science research for established strategies. Research on epidemiological, behavioral, and social aspects of preventive and therapeutic interventions will be incorporated where appropriate. It is expected that Network clinical studies will be conducted at domestic and/or international sites depending on access to appropriate populations, sufficient disease burden or event rates, and timely participant accrual. International sites can offer opportunities for benefit to Americans living with, or at risk for acquiring, HIV and other HIV-associated infections when the proposed research cannot be accomplished as effectively or efficiently through domestic sites alone. Specific responsibilities include: 

  • Governance: Establish clear structures for communication, decision-making authority, collaboration, and resource distribution with NIAID, ICO partners, and external collaborators.  
  • Research Agenda: Collaborate with LC and SDMC to set and refine scientific priorities, engage stakeholders, and ensure alignment with NIAID and NIH goals.  
  • Innovation: Foster innovative approaches, including public-private partnerships, to advance HIV clinical research.  
  • Community Engagement: Integrate community participation across Network activities.
  • Training and Mentoring: Provide comprehensive training and promote mentorship, including protocol training and support for early-career investigators.  
  • Quality Management: Ensure compliance, study participant protection, and data integrity through robust Quality Assurance and Quality Control processes; support audits and inspections.
  • Clinical Operations: Manage and oversee clinical studies, including protocol development, site selection, progress tracking, and results dissemination, in coordination with Network partners.  
  • Clinical Research Sites (CRSs) and Protocol-Specific Sites (PS): Establish efficient processes for identifying, qualifying, and approving sites to meet unique study needs.  
  • Network Management: Develop policies, Standard Operating Procedures (SOPs), budgets, and communication plans; implement effective project management for efficient protocol conduct, study completion and to allow cross-network coordination and reporting.  
  • Network Meetings: Hold annual meetings to share findings and facilitate collaborations, with participation from key Network personnel, NIH staff, and external advisors. 

 The Research Agendas for the four Networks are as follows: 

1. HIV/AIDS Adult Therapeutics Clinical Trials Network – Responsible for supporting the advancement of therapeutics research toward the treatment and cure of adults living with HIV including implementation science and clinical research to improve the management of HIV-related co-morbidities, coinfections and aging. Key aspects to this research agenda include: 

  • Implementation Science - strategies to adapt, deliver, and expand the reach, scale-up, and sustainability of evidence-based treatment for HIV and HIV-associated diseases.  

  • Novel and Durable Interventions for HIV – strategies to achieve durable HIV suppression and improve treatment outcomes for adults living with HIV.  

  • Anti-retroviral (ART)-Free Remission (HIV Cure) - strategies to eradicate HIV or sustain virologic remission through immune-based interventions. 

  • Complications and Non-Infectious Comorbidities – strategies to improve the prevention, treatment and management of high-impact co-morbidities in PWH (e.g., neurocognitive, substance use disorders, cardiovascular diseases, lung diseases, diabetic and related metabolic and endocrine conditions, kidney, urologic and hematologic disease, oropharyngeal complications, aging associated conditions).  

  • Viral Hepatitis - novel treatment strategies for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.  

  • Tuberculosis - novel therapeutics and combination treatments for drug-sensitive and -resistant tuberculosis (TB).  

Additionally, this Network will be responsible for the clinical research infrastructure to support early-stage pilot trials of novel products and approaches; opportunities for intensive sampling of potential tissue reservoirs of HIV; and specialized laboratory capabilities for virologic and immunologic analyses.   

2. HIV/AIDS Maternal, Adolescent, and Pediatric Clinical Trials Network – Responsible for advancing research to generate the evidence base on novel, innovative therapies, interventions, methods, and strategic approaches for HIV and HIV-associated conditions in infants, children, adolescents, and pregnant/postpartum women, integrating implementation science across the product development lifecycle to speed their adoption and scale-up.  Key aspects to this research agenda include: 

  • Implementation Science - strategies to adapt, deliver and scale evidence-based interventions that optimize prevention for pregnant and breastfeeding women, strengthen maternal antiretroviral therapy (ART), tailor infant prophylaxis, and expand early and repeat HIV testing for breastfeeding infants and children.  

  • HIV Treatment and Prevention Innovations - antiretroviral drug and regimen innovations in appropriate long-acting (or pediatric-friendly oral) formulations for pediatric and maternal populations and infant postnatal prophylaxis.  

  • ART-Free Remission (HIV Cure) - strategies to achieve sustained virologic remission in pediatric populations, including strategies initiated in the immediate newborn period. 

  • Treatment and Prevention of Tuberculosis and Other HIV-associated Co-Infections - new drugs and regimens for treatment and prevention of drug-sensitive and resistant TB disease, both pulmonary and extrapulmonary (including central nervous system [CNS]); address treatment needs for congenital syphilis, viral hepatitis (B and C), and other important HIV-associated co-occurring infections.  

  • Brain and Mental Health and Other HIV-associated Comorbidities - Neuroprotective and neurotoxic effects of ART to preserve neurocognitive development and mental health in infants, children, and adolescents. Evaluate novel preventive and therapeutic approaches for other high-priority diseases and co-occurring conditions  

3. HIV Prevention Clinical Trials Network – Responsible for advancing products and strategies to meet the needs of populations vulnerable to HIV acquisition including adults, adolescents and pregnant women, through the integration of biomedical, socio-behavioral and structural prevention strategies, in partnership with implementing agencies and organizations. Key aspects to this research agenda include:  

  • Implementation Science – strategies to optimize deployment of and improve access to biomedical and socio-behavioral evidence-based interventions for HIV prevention. 

  • Integrated Prevention Strategies - integration of socio-behavioral research to optimize HIV prevention outcomes tailored to the population and context, to improve HIV treatment uptake and adherence, retention in care, and reduction of HIV risk. 

  • Novel Biomedical HIV Prevention and Delivery Systems - strategies and delivery methods that meet the needs of varied populations and help address the challenges of adherence. Multipurpose technologies (MPTs) – products designed to simultaneously protect against multiple sexual and reproductive health issues and potentially medications to treat or prevent other health conditions.  

  • Intersection of HIV and Other Sexually Transmitted Infections (STIs) - prevention and treatment strategies to address interaction between HIV and STIs. 

4. Immune-Based Prevention Trials Network – Responsible for the discovery and advancement of immune-based strategies to protect against HIV infection and associated infectious diseases, including TB and STIs, through Phase 1–3 clinical trials designed to answer key immunologic research questions to inform future candidate design, define correlates of protection, and identify safe and efficacious preventative regimens. Key aspects to this research agenda include: 

  • Antibody-Mediated Prevention for HIV - design and conduct Phase 1–3 trials of passive immunization strategies.  

  • Induced-Immunity for Prevention of HIV Acquisition - evaluate immunogens, immune modulators and adjuvants; and combinations of immunogens with antiretroviral drugs and other HIV prevention modalities.  Conduct rapid, iterative "discovery medicine" trials to evaluate novel immunogens and adjuvants.  

  • Analytical Treatment Interruption (ATI) Strategies - studies in PWH to evaluate viral control to inform HIV immune-based prevention approaches and immunotherapy development.  

  • Immune-based Prevention Strategies Against Other HIV-associated Infectious Diseases - evaluate interventions against other infectious diseases (e.g., TB and STIs) and how these diseases may influence the safety and effectiveness of HIV prevention approaches.  

  • Integration of Implementation and Behavioral Science Research - integration across all stages of immune-based product development and evaluation, assessing acceptability and mode of intervention. 

  • Determinants of Immune Function and Intervention Effectiveness - evaluate how the microbiome, diet and environmental exposures share or alter immune function and the effectiveness of prevention interventions.   

Cross-Network Collaboration: Each Network will be expected to collaborate with other HIV/AIDS Networks and lend its expertise where other Networks serve as the lead. Opportunities for cross-network research collaboration will be developed post-award in conjunction with NIAID and other NIH staff.  

Other Research Areas: Each Network may have the opportunity to contribute to the research agenda for support of the development of strategies, interventions, and products for the rapid response against other/emerging infectious diseases (not listed above) of public health importance and to implement clinical trials in support of this agenda. The research agenda for those efforts will be developed post-award through cross-network, joint leadership efforts in conjunction with NIAID and other NIH staff.  

Core and Protocol Funds 

Funding to carry out the Network's research agenda falls into two categories: 

Core Funds: initial fixed-base funding for infrastructure and salary support that is not protocol-specific. NIAID will provide core funds directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis.  

Protocol Funds (PF): support to conduct protocols, including protocol-specific infrastructure or other requirements needed to conduct protocols at a clinical research site. PF varies annually, depending on costs of ongoing protocols. NIAID anticipates providing PF directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis.  

The LOC will estimate PF needs for the Network (salary and non-salary PF) based on communications with the LC, SDMC and CTUs/CRSs and submit an annual budget request to NIAID.  

During the project period, additional protocol-specific (PS) sites may be added as needed to execute a specific protocol. These will be reviewed individually and, if approved, supported via a vendor agreement. These PS sites will be closed upon completion of the protocol. 

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New
Renewal - Renewals of RFA-AI-19-003, RFA-AI-19-004, RFA-AI-19-005, and RFA-AI-19-006

The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Required: Only accepting applications that propose clinical trial(s).

Funds Available and Anticipated Number of Awards

NIAID and partner components intend to commit an estimated total of $48M to fund 4 awards in FY2028.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award Project Period

The project period must be 7 years. 

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions - Includes all types

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession

Other

  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations

Foreign Organizations/Foreign Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information

  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM.
    • Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.
  • eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. 

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

2. Cost Sharing

This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations

All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed, with the following additional instructions:

The Research Strategy must consist of the following sub-sections with the indicated page limits:

Sub-section A. Overview of the Proposed Leadership and Operations Center (LOC), one required - 12 pages

Sub-section B. Scientific Leadership: Structure and Governance, one required - 12 pages

Sub-section C. Clinical Research Agenda, one required - 30 pages

Sub-section D. Training and Mentoring, one required - 6 pages

Sub-section E. Evaluation and Improvement, one required - 6 pages

Sub-section F. Quality Management, one required - 12 pages

Sub-section G. Clinical Operations, one required - 30 pages

Sub-section H. Collaboration with the LC, SDMC and CTUs/CRSs, one required - 12 pages

Sub-section I. Communication, Collaboration and Harmonization, one required - 6 pages

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Senior/Key Person Profile

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Within the Common Forms for Biographical Sketch and NIH Biographical Sketch Supplement, highlight the following:

  • The relevant experience in leading and managing a complex clinical research program, including the roles and responsibilities served. Describe relevant expertise in protocol design, regulatory compliance, site selection, study implementation and coordination.
  • The project management staff describe the experience, including roles and responsibilities served, and resource management expertise for clinical research programs of similar size and scope.

R&R Budget

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Only request Core Funds for the initial fixed-base funding, infrastructure and salary support that is not protocol-specific (e.g., administrative and management support, community education and engagement structures and activities, clinical quality management activities, record retention).

Do not request Protocol Funds (PF) (e.g., protocol-specific personnel salary, participant recruitment and retention, protocol required tests and evaluations, participant reimbursement, community education and engagement structures and activities, and protocol specimen shipment and storage).

If a single PD/PI is proposed, the PD/PI will be required to devote at least 6 person-months of effort to the project. If two or more PD(s)/PI(s) are named, each PD/PI must devote at least 3.6 person- months of effort to the project.

R&R Subaward Budget

All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Research Plan

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Specific Aims: Describe the scientific aims of the Leadership and Operations Center (LOC). Each application in response to this NOFO must address only the research agenda of one HIV/AIDS Clinical Trials Network and must state which one of the four HIV/AIDS Clinical Trials Networks the LOC proposes to support.

Research Strategy: The Research Strategy section must consist of sub-sections A-I as designated below.

Sub-section A. Overview of the Proposed Leadership and Operations Center (LOC)

  • Provide a high-level overview of the key clinical research questions and explain how the LOC research agenda will address them. 
  • Describe the overall strategy and methodologies to be used to accomplish the specific aims of the LOC. Describe any novel (or refinements/improvements) in concepts, approaches, or methodologies that are being developed or used and any advantage that may have over existing methodologies with respect to the development, design, and conduct of clinical trials. Include approaches to the utilization of digital health tools and remote/decentralized trial capabilities to expand access and participation for study participants as needed for successful trial implementation.
  • Explain how the LOC will be integrated with the Laboratory Center (LC), Statistical and Data Management Center (SDMC) and Clinical Trials Units (CTUs) and leveraged to meet the goals of the overall Network.
  • Briefly explain how the use of international sites will directly inform interventions or strategies to benefit Americans living with, or at risk for acquiring, HIV and other HIV-associated infections.
  • For renewal applications: Progress Reports should be included in sub-section A.

Sub-section B. Scientific Leadership: Structure and Governance

  • Describe the overall LOC structure, including staffing roles and responsibilities, with an organizational chart identifying senior/key personnel, and describe how the LOC will interface with the LC, SDMC, and CTUs. Describe how this structure supports effective leadership of overall Network activities. 
  • Describe the LOC governance framework, including decision-making committees (e.g., EMC), along with their composition, roles, and authorities.
  • Explain processes for setting priorities, adapting to evolving needs, aligning and reallocating Network resources, discontinuing unproductive activities, and exchanging scientific and programmatic information with NIH and stakeholders to assess progress and pursue new research and collaboration opportunities.

Sub-section C. Clinical Research Agenda

  • Describe key knowledge gaps and future opportunities in HIV research and outline a cohesive HIV clinical research agenda with clear goals, priority areas, benchmarks, and timelines.
  • For each research agenda area that the LOC will oversee, explain its relevance to the HIV field, its potential to address ongoing challenges and the key population characteristics required to support the work.
  • Describe how implementation science concepts will be incorporated, prioritized, and evaluated; outline strategies for embedding pre-implementation objectives in trials, transitioning from efficacy to effectiveness studies, testing strategies to improve engagement in care, and collaborating with partners to launch implementation studies.
  • Summarize the required scientific staff expertise, laboratory and site capabilities, community representation plans, and processes for integrating external expertise and novel ideas into the agenda.
  • Describe how the Network will leverage innovative trial designs and novel statistical methods to streamline trials and accelerate data generation. 
  • Describe how the LOC structure will support rapid response to new scientific opportunities, how sub-studies and external investigator proposals will be reviewed and approved, and how access to specimens and data will be managed.
  • Describe the process for the incorporation of new researchers into the Network, within the context of conducting the Network's research agenda.
  • Outline processes and frequency for reviewing research priorities and concepts for merit and feasibility, obtaining external assessments, adjusting the agenda as needed, evaluating decision-making committees, and fostering partnerships with agencies, organizations, and industry to ensure access to needed tools and products.

For applications within the following Research Agendas, including the following:

1. HIV/AIDS Adult Therapeutics – Applications should describe:

  • Plans to incorporate discrete implementation studies or implementation research aims integrated into interventional clinical trials. 
  • The infrastructure, expertise, and partnerships needed to identify and conduct high-priority implementation studies.
  • Plans to evaluate novel and durable interventions for HIV, with the integration of behavioral, biomedical and structural interventions, and how they would improve treatment outcomes and support long-term viral suppression in adults living with HIV.
  • The research plan for strategies intended to eradicate HIV or sustain virologic remission without continuous antiretroviral therapy. 
  • Plans for clinical trials designed to improve prevention or management of major complications and comorbidities affecting people with HIV. Identify the targeted condition(s) and explain the expected clinical impact. Address the development of integrated care models to facilitate uptake into standards of care.
  • Plans for research on novel preventive or treatment strategies for HBV and/or HCV infection in the context of HIV. 
  • Plans for research on tuberculosis (TB) in the context of HIV. Address novel therapeutics and combination regimens for drug-sensitive and drug-resistant TB disease, including extrapulmonary TB.
  • The evaluation strategies to maximize public health impact of interventions to prevent and treat HBV, HCV and TB disease among PWH.
  • How small proof of concept or Phase I (single site) clinical trials will be rapidly implemented when trials of high priority are identified. 
  • How treatment-related protocols will incorporate valid assessments of treatment adherence, strategies to promote adherence to clinical trial protocols and investigational therapies, and concurrent scientific expertise. 

2. HIV/AIDS Maternal, Adolescent, and Pediatric – Applications should describe:

  • Plans to advance implementation science for maternal, pediatric, and adolescent populations through contextually appropriate strategies to scale evidence-based interventions in real-world care settings. Describe use of hybrid effectiveness-implementation designs and approaches to identify children, link them to care, improve ART coverage and viral suppression and address multilevel barriers and facilitators to equitable adoption and scale-up.
  • How the Network will accelerate evaluation of antiretroviral innovations, including long-acting and pediatric-friendly oral formulations, in maternal and pediatric populations. Address postnatal prophylaxis strategies, including long-acting small molecules and biologic agents, for infants at high risk of vertical HIV acquisition.
  • Strategies to evaluate interventions aimed at pediatric ART-free remission, including very early diagnosis and treatment initiated in the newborn period, to improve future remission potential.
  • Plans to evaluate new drugs and regimens for treatment and prevention of drug-sensitive and drug-resistant TB, including pulmonary, extrapulmonary, and central nervous system disease, and to address unmet needs related to congenital syphilis, HBV, HCV, and other important HIV-associated coinfections.
  • Plans for research on brain and mental health and other HIV-associated comorbidities. Explain the relevance to HIV treatment and long-term developmental outcomes.

3. HIV/AIDS Prevention – Applications should describe:

  • How the Network will advance and expand implementation science for biomedical and socio-behavioral HIV prevention strategies by developing and evaluating approaches to scale evidence-based interventions for vulnerable populations. Explain how the proposed work will improve prevention reach, uptake, or sustainability.
  • How the proposed implementation science research includes health system approaches, use of real-world evidence, and validated implementation science frameworks, in partnership with local stakeholders, including community representatives and implementers.
  • Plans for integrated prevention packages that combine biomedical and socio-behavioral approaches tailored to specific populations and contexts and designed to improve prevention uptake, adherence, retention in services, reduction of HIV risk, and engagement in comprehensive health services. Describe how such strategies will be delivered across varied venues and service platforms to overcome structural and systems-level barriers.
  • Plans to evaluate novel biomedical HIV prevention interventions and delivery systems, including long-acting agents, sustained-release systems, and other innovative products or methods that increase choice and address adherence challenges. Include strategies to assess end-user preferences and preferred product characteristics to inform intervention development and optimization.
  • Clinical product development activities for MPTs, including methods to determine end-user preferred characteristics.
  • STI prevention or treatment strategies that include novel agents, point-of-care diagnostics, or biomarkers of adherence to STI prevention and treatment products. Explain how the proposed work addresses the interaction between HIV and STIs and improves prevention or treatment outcomes. 

4. Immune-Based Preventions – Applications should describe:

  • Plans for clinical trials of antibody-mediated HIV prevention strategies. Address approaches to define protective antibody titers and functional characteristics, including pharmacokinetics, tissue distribution, and other features relevant to prevention.
  • Plans for clinical trials of induced-immunity approaches to prevent HIV acquisition in adult and pediatric populations, including the evaluation of immunogens, immune modulators, adjuvants, and combinations with antiretroviral drugs and other prevention modalities.
  • How the Network will conduct rapid, iterative discovery medicine trials to evaluate novel immunogens and adjuvants designed to induce protective immunity and the approaches to assess the durability of immune responses to inform the design of optimal boosting strategies.
  • How the Network will conduct carefully designed ATI studies in people with HIV to evaluate viral control and inform immune-based prevention and immunotherapy development.
  • Plans for immune-based prevention trials against other HIV-associated infectious diseases, including TB and STIs, including a focus on how these infections may affect the safety and effectiveness of immune-based HIV prevention approaches.
  • How implementation and behavioral science will be incorporated across all stages of immune-based product development. Address acceptability, mode of intervention, vulnerable populations, community perceptions and explain how these factors will inform product development and trial conduct.
  • Plans for evaluating how the microbiome, diet, and environmental exposures shape or alter immune function and the effectiveness of prevention interventions.

Sub-section D. Training and Mentoring

Describe how the training needs (e.g., Network-specific, NIAID-mandated, protocol specific, site activation, etc.) of LOC scientific staff will be determined, provided and evaluated, and how necessary changes in training will be decided and implemented. Discuss how the LOC will coordinate across the Network to ensure appropriate training needs are met.

Provide plans for clinical research mentoring opportunities and integration of early-career investigators.

Sub-section E. Evaluation and Improvement

Describe how the performance of the LOC will be evaluated and improved over the award period. Describe the process for re-evaluation of operational performance of the overall Network in the conduct of Network activities, including the financial management of Network resources. Provide the criteria for reallocation, if necessary, of resources to ensure efficient resource management. Include a discussion of metrics that may be used to determine both productivity and quality of the results generated by the Network over the duration of the award. Describe processes for the resolution of performance problems for the Network and proposed processes for the remediation/improvement of performance. Do not name or contact anticipated collaborators; rather, list areas of expertise that will be sought, frequency of assessments, etc.

Sub-section F. Quality Management

Describe the approach to quality management for LOC activities and LOC-coordinated management of efforts of the SDMC, LC and CTUs/CRSs needed for achieving and maintaining compliance with International Council for Harmonization E6 (ICHE6), 21CFR Part 11, Good Documentation Practice (GDP), Good Manufacturing Practice (GMP), Division of AIDS (DAIDS) Clinical Research Policies and Standard Operating Procedures (SOPs), and other standards.

Describe the coordination of the overall LOC Quality Management Plan with individual quality plans developed for each protocol. Address quality control procedures including real time systemic checks of protocol and regulatory adherence; quality assurance including regular auditing, and quality improvement based on evaluation and education.

Sub-section G: Clinical Operations

Organizational Structure and Management Plan

Describe the LOC Clinical Operations structure and functions, including day-to-day management, coordination of scientific and fiscal responsibilities, financial oversight of Network resources, cost-efficiency strategies, and processes for soliciting and managing subcontracts and acquired services.

Protocol Development and Project Management

Outline the end-to-end protocol development process–from concept approval through NIAID approval and site distribution–ensuring compliance with applicable policies and regulations (including NIAID clinical research policies and SOPs, ICHE6, and 21 CFR Part 11); define team composition, roles, decision-making processes, budget development, resource allocation, benchmark tracking, contingency planning, and expedited pathways for high-priority studies. 

Describe how protocol budgets will be developed and how protocol funding will be linked to resource requirements. Describe the process for determination of salary and non-salary PF allocation to the CTUs/CRSs.

Clinical Research Site Selection

Describe the approach to assessing and selecting clinical research sites, addressing capacity gaps (including adding non-Network sites when necessary), and ensuring transparent coordination with NIAID, CTUs/CRSs, affiliated laboratories, and clinical research support programs.

Protocol Implementation and Performance Oversight

Explain strategies for implementing and completing protocols on time and within budget, integrating NIAID contract resources, fast-tracking high-priority studies, delivering protocol-specific training, monitoring study progress, evaluating site performance, and addressing underperformance.

Sub-section H. Collaboration with LC, SDMC and CTUs/CRSs

Describe plans, processes and procedures for interacting and collaborating with the LC. Describe the collaboration with the LC in the evolution of the research agenda, and in development and implementation of protocols. Describe the process for projecting needs and costs for laboratory services including capacity to conduct routine and protocol-specific laboratory assays, conduct laboratory activation and training, and provide repository services. Describe plans for LC involvement with local, regional and specialty laboratories. Describe the process for tracking actual use of protocol-specific laboratory services compared to projected needs and adjusting capacity.

Describe plans, processes and procedures for interacting and collaborating with the SDMC. Discuss how the LOC will facilitate the use of data systems by the SDMC that are compliant with 21 CFR and ICH guidelines. Describe coordination of activities with the SDMC staff including, but not limited to: protocol design, development and implementation, data analysis, preparation of data summaries (within and across protocols), and publication of results. Describe plans for coordination of responsibilities of the LOC and SDMC in study preparation at the data management and site level including protocol-specific training.

Describe how the LOC will interact and collaborate with the CTUs and CRSs, including the following:

  • Conducting site feasibility assessments to evaluate capacity, capabilities, laboratory access, pharmacy security, and ability to recruit and retain the target population(s).
  • Soliciting, reviewing, and selecting CRSs to implement specific protocols based on objective criteria. Establishing timelines for protocol activation and developing procedures for protocol-specific training to ensure readiness and consistent study conduct across CRSs.
  • Managing study products; verifying laboratory and specimen management capabilities; ensuring capacity for data collection, analysis, and secure transmission to the SDMC.
  • Providing participant safety oversight and regulatory compliance.
  • Establishing decision-making processes for modifying or reducing site capacity, including site closure if necessary.

Sub-section I. Communication, Collaboration and Harmonization

Describe processes for Network-wide communications. Include plans for communicating and publishing results from Network research.

Describe plans for community engagement, including a description of the role and nature of community input, from individuals and from groups, in all aspects of the Network. Do not name or contact specific community-based organizations (CBOs) and non-government organizations (NGO) community advisors or organizations. Do provide the names, expertise/experience, roles and responsibilities of paid LOC staff who will be involved in community activities.

Describe how the LOC will work with other Network LOCs to ensure efficient utilization of NIH resources to address cross-network hypotheses and endpoints. Specifically include plans to develop, implement and oversee clinical trials that address scientific questions of mutual interest. 

Provide a detailed plan to work with other LOCs, SDMCs, and LCs to identify and harmonize processes for working with CTUs and CRSs.

Letters of Support:

Provide appropriate letters of support limited to collaborators who have a significant role in the application. Note that letters establishing intra-network and cross-network collaborations are not necessary.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s): 

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

  • A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed.

Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide.

  • No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide, with the following additional instructions:

Other Requested Information

For Renewal applications with ongoing clinical studies, applicants must include a list of all ongoing clinical studies and/or the unique ClinicalTrials.gov identifiers. All information must be combined in one single attachment using the filename "Ongoing Clinical Studies". If appropriate, please indicate for each study the NIAID Division of AIDS (DAIDS)-defined study status.

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the How to Apply - Application Guide must be followed with the following additional instructions:

Although applicants must be prepared for clinical trials, definite plans for such involvement will not be possible at time of application. A Study Record MUST not be completed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

All Applications must add and complete the Delayed Onset Study record and must check box "Anticipated Clinical Trial?".

Study Title: use "Multiple Delayed-Onset Studies"

Justification Attachment: Indicate that each clinical study protocol developed during the project period will be subject to approval through a procedure that involves an initial concept submission and subsequent review by the HIV/AIDS Clinical Trials Network and NIAID. If the concept receives approval, the next stage will be development of the protocol, which also must undergo review and approval prior to implementation through the HIV/AIDS Clinical Trials Network.

PHS Assignment Request Form

All instructions in the How to Apply - Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.

  • Awards issued under this notice of funding opportunity (NOFO) will be incrementally funded awards and may be issued for project periods of up to 7 years. Multi-year funded grants will not be allowed.
  • Grants awarded under this NOFO will not be provided the authority to automatically extend the final budget period one time to 12 months beyond the original project period end date shown in the Notice of Award. All extensions, including the first extension, will require prior approval. Please note a 7-year grant does not qualify for a no-cost extension.
  • Progress and financial reporting will be required and reviewed annually. All funds must be expended within the approved project period.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed. 

Mandatory Disclosure

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.35.

Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov. 

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

 

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

Specific to this NOFO:

  • How well does the application address the proposed research agenda and to what extent does it address key clinical questions in HIV research?

 

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

Specific to this NOFO:

  • To what extent do the PD/PI(s) and other key personnel have documented experience in directing clinical research projects of comparable size and scope required to address the objectives and scope of the Network? How well do they demonstrate appropriate expertise in protocol design, regulatory compliance, site selection, and study implementation?

 

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?


 

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

Does the application adequately address the following, if applicable?

Study Design

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, sex, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

Data Management and Statistical Analysis

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

Specific to this NOFO:

  • To what extent are the Network's structure and governance adequate to ensure that the LOC continues to address the most significant needs and opportunities in HIV clinical research?
  • How well-defined and transparent are the proposed governance structures and processes for resource alignment with Network priorities?
  • How adequate, feasible, and operationally sound are the plans for managing, supporting, tracking, and implementing protocols, including coordination of scientific and fiscal responsibilities across the Network?
  • How well does the application describe how implementation science research concepts will be solicited, prioritized, and evaluated in relationship to the rest of the research agenda?
  • How appropriate and feasible are the proposed training and mentoring plans?
  • How rigorous and useful are the proposed approaches to evaluating LOC performance and implementing improvements?
  • How well does the LOC Quality Management Plan support regulatory compliance across clinical trials?
  • How effective and feasible are the plans to engage the community and incorporate community input into decision-making?

 

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?

If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?


Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

 

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?


 

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.


 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for inclusion. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research. 


 

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following three points: (1) a complete description of all proposed procedures including the species, strains, ages, sex, and total numbers of animals to be used; (2) justifications that the species is appropriate for the proposed research and why the research goals cannot be accomplished using an alternative non-animal model; and (3) interventions including analgesia, anesthesia, sedation, palliative care, and humane endpoints that will be used to limit any unavoidable discomfort, distress, pain and injury in the conduct of scientifically valuable research. Methods of euthanasia and justification for selected methods, if NOT consistent with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals, is also required but is found in a separate section of the application. For additional information on review of the Vertebrate Animals Section, please refer to the Worksheet for Review of the Vertebrate Animals Section.


 

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.


 

For Resubmissions (as applicable), the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.


 

For Renewals (as applicable), the committee will consider the progress made in the last funding period.


 

For Revisions (as applicable), the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.


Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

 

Not Applicable.


 

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).


 

Reviewers will comment on whether the Resource Sharing Plan(s) (e.g., Sharing Model Organisms) or the rationale for not sharing the resources, is reasonable.


 

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.


 

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.


2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by CSR, in accordance with NIH peer review policies and practices, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Requests for reconsideration of initial peer review will not be accepted for applications submitted in response to this NOFO. 

Applications will be assigned on the basis of established referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. Funding decisions are based on the core tenets of a unified funding strategy, see ICO Funding Policies and Considerations. Applicants are strongly encouraged to also refer to the ICO-specific funding policies and considerations pages linked therein that build upon the agency-wide framework.

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement Section 2.5.1. Just-in-Time Procedures. This request is not a Notice of Award nor should it be construed to be an indicator of possible funding.

Prior to making an award, NIH reviews an applicant's federal award history in SAM.gov to ensure sound business practices. An applicant can review and comment on any information in the Responsibility/Qualification records available in SAM.gov.  NIH will consider any comments by the applicant in the Responsibility/Qualification records in SAM.gov to ascertain the applicant's integrity, business ethics, and performance record of managing Federal awards per 2 CFR Part 200.206 "Federal awarding agency review of risk posed by applicants."  This provision will apply to all NIH grants and cooperative agreements except fellowships.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement Section 2.4.4 Disposition of Applications.

Section VI. Award Administration Information

1. Award Notices

A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient's business official.

In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk.  For more information on the Notice of Award, please refer to the NIH Grants Policy Statement Section 5. The Notice of Award and NIH Grants & Funding website, see Award Process.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm

Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

2. Administrative and National Policy Requirements

The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:

All federal statutes and regulations relevant to federal financial assistance, including those highlighted in NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.

By applying for or accepting federal funds from HHS, recipients certify compliance with all federal antidiscrimination laws and these requirements and that complying with those laws is a material condition of receiving federal funding streams. Recipients are responsible for ensuring subrecipients, contractors, and partners also comply.

Applicants and recipients are strongly encouraged to refer to the NIH Director's Statement of Priorities, entitled "Advancing NIH's Mission Through a Unified Strategy." 

Recipients are responsible for ensuring that their activities comply with all applicable federal regulations. Pursuant to 2 CFR 200.340, by accepting an NIH award, the recipient agrees that continued funding for the award is contingent upon the availability of appropriated funds, recipient satisfactory performance, compliance with the Terms and Conditions of the award, and may also otherwise be terminated, to the extent authorized by law, if the agency determines that the award no longer effectuates the program goals or agency priorities, in line with 2 CFR 200.340(a)(4).

Pursuant to the Cybersecurity Act of 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.

Successful recipients under this NOFO agree that:

When recipients, subrecipients, or third-party entities have:

  • ongoing and consistent access to HHS owned or operated information or operational technology systems; and
  • receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.

Cybersecurity plans and procedures must at minimum include the following:

  • Develop cybersecurity plans and procedures, modeled after the NIST Cybersecurity framework, to protect HHS systems and data:
    • Identify:
      • Develop an inventory of all assets and accounts with access to HHS owned and operated information or operational technology systems or which obtain PII or PHI for the purposes of the award.
    • Protect:
      • Limit access to HHS owned and operated systems to only those in need of access to complete reward activities.
      • Require all staff to complete annual cybersecurity and privacy awareness training. Visit 405(d): Knowledge on Demand (hhs.gov) to obtain free trainings, if needed.
      • Enable multifactor authentication for all employees, subrecipients, and third-party entities to access HHS owned and operated information or operational technology systems.
      • Regularly backup sensitive data and test backups.
    • Detect:
      • Install anti-virus or anti-malware software on all devices, servers, and accounts used to connect to HHS owned and operated systems.
    • Respond:
      • Develop an incident response plan. See Incident-Response-Plan-Basics_508c.pdf (cisa.gov) to learn about developing incident response plans.
      • Have cybersecurity incident reporting procedures that ensure the relevant HHS awarding agencies are notified of a cybersecurity incident within 48 hours of discovery. A cybersecurity incident is defined as an unplanned interruption to a technology service or reduction in the quality of a technology service, or an occurrence that actually or potentially jeopardizes the confidentiality, integrity, or availability of an information system or the information the system processes, stores, or transmits.
    • Recover:
      • Investigate incidents and plug any security gaps identified. 

All activities proposed in your application and budget narrative must align with applicable law, including but not limited to statutes, executive orders, federal regulations and applicable judicial holdings.  Accordingly, discretionary awards shall not be used to fund, promote, encourage, subsidize, or facilitate; racial preferences or other forms of racial discrimination by the recipient, including activities where race or intentional proxies for race will be used as a selection criterion for employment or program participation; denial by the recipient of the sex binary in humans, or the belief that sex is a chosen or mutable characteristic; illegal immigration; or any other initiatives that compromise public safety.  If an application does not align, the application will not receive funding to the extent permitted by law and applicable court orders.

For applications involving substance abuse, the application must not support harm reduction. Please see Updated Funding Guidance for Recipients on Supplies and Services.

For applications involving funding Medication-Assisted Treatment (MAT) or medications for opioid use disorder (MOUD), this funding should be used to provide comprehensive treatment and recovery support services rather than medication-only models for opioid use disorder. Services should include medications, where clinically indicated, in conjunction with psychosocial and other treatment and recovery support services. Funding can also be used to support individualized tapering and discontinuation of medications when clinically indicated. Please see Updated Funding Guidance for Recipients on  MAT/MOUD.

As of October 1, 2025, HHS has adopted 2 CFR Part 200, with some modifications included in 2 CFR Part 300. These regulations replace those in 45 CFR Part 75. However, for NIH, under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs in 45 CFR 75 continue to apply to NIH awards. Consistent with the statute, NIH will not apply updated thresholds outlined within 2 CFR Part 200, at this time.

In administering programs under this and all funding announcements, NIH prioritizes: 

  • Research involving rigorous scientific methods, including for studies related to children and adolescents, where NIH is committed to approaches that reflect the highest standards of clinical care and child safety. 
  • Biological and physiological integrity: Recognizing the relevance of biological sex to health outcomes, NIH encourages applicants to account for sex-based health factors in program design, data collection, and service delivery where scientifically appropriate.
  • NIH will implement these priorities consistent with applicable laws, regulations, court orders, and all required administrative procedures. Applicants are encouraged to describe how their proposed programs align with these priorities in their project narratives. Funded activities must advance NIH's vision of protecting and improving the health and well-being of Americans. The particular focus is on those who are medically vulnerable, or live in areas with limited access to care. NIH's duty is to serve wisely, effectively, and with measurable results that justify every taxpayer dollar invested. 

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (HHS) grant administration regulations at 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the recipients for the project as a whole, although specific tasks and activities may be shared among the recipients and NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

  • In collaboration with the PD(s)/PI(s) of the Laboratory Center (LC) and Statistical and Data Management Center (SDMC): 
    • Establishing policies and procedures for collaboration with Network elements and decision-making within the Leadership and Operations Center (LOC) to adapt to evolving research priorities over time.
    • Maintaining close communication and coordination, including convening or participating in meetings and teleconferences with the LC, SDMC, and affiliated Clinical Trials Units/Clinical Research Sites (CTU/CRSs).
    • Verifying that studies are conducted in compliance with all applicable regulations including 21 CFR Part 11 and ICHE6R2 guidelines.
    • Managing involvement of industry or any other third party in studies supported by this award. Informing NIAID in the event that Network recipient institutions enter into agreements that provide essential support to NIAID-sponsored clinical studies but are not actions as part of the Network awards. 
    • Establishing and adhering to policies and standard operating procedures, ensuring compliance with NIAID DAIDS clinical research policies. Providing policies and standard operating procedures upon request to NIAID within 90 days of issuance of an award.
    • Coordinating with NIAID DAIDS Clinical Research Products Management Center (CRPMC) contractor to facilitate availability and distribution of study products. Working closely with Clinical Monitors or Regulatory Auditors to ensure proper completion of all actions and steps associated with on-site monitoring or auditing, including review of corrective and preventative action plans when problems are detected. 
    • Ensuring that protocol suspensions are implemented immediately on notification and remains in effect until notified that NIAID has conducted any required audit and the audit report or remedial action is accepted by NIAID. The PD(s)/PI(s) will ensure that during the suspension period, no funds from this award are allowed for new accruals.
  • Maintaining primary responsibility for the scientific leadership, administration and coordination of all Network activities, including, but are not limited to:
    • Developing and implementing procedures for selecting and prioritizing research concepts.
    • Ensuring that protocol development is initiated only when sufficient preclinical safety and scientific evidence exist, study product supply and funding are secured, and the Network and sites have the capacity and commitment to complete all phases of the study–from development through publication.
    • Selecting the protocol team and sites, assessing site capacity, ensuring appropriate expertise (including Community Advisory Board and DAIDS representation), confirming adequate protocol chair commitment, and completing study reports on time.
    • Ensuring that protocol implementation and oversight follows predefined criteria for operational futility and endpoint feasibility, obtaining NIAID approval, and ensuring all required resources, site approvals, and data management plans are in place before initiation.
    • Ensuring ongoing monitoring of study progress and participant safety, with regular reporting to NIAID and timely communication of results to participants and the community.
    • Developing, training, and supporting Network community advisory boards.
    • Implementing procedures for regular transparent assessment of CTU/CRS performance, which must include processes for the addition, reduction, expansion or elimination of Network-affiliated CTUs/CRSs.
    • Determining, recommending, requesting, and adjusting protocol funding for LOC, LC, SDMC and Network-affiliated CTUs/CRSs.
    • Ensuring timely submission to NIAID of all required administrative, regulatory, and oversight materials, including sponsor reports, protocol and accrual data, site and personnel information, training records, and Protocol Fund (PF) reports.
    • Establishing performance measures for evaluating the efficiency and effectiveness of the LOC, LC, SDMC, and Network-affiliated CTUs/CRSs.
  • Recipients will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

  • Facilitating coordination among the NIAID- and NIH-supported Clinical Trials Networks and research groups, clinical research support programs, and other U.S. Government agencies, promoting collaborations and facilitating information exchange.
  • Participating in scientific working groups and protocol teams, and as a voting member (sharing one vote) in scientific committees. Identifying scientific gaps and organizing meetings to facilitate exchange of scientific and regulatory information, including during Network meetings.  
  • Coordinating contract resources that facilitate the provision of support services for clinical trials.
  • Facilitating access to NIAID DAIDS Clinical Research Products Management Center (CRPMC) contractor to facilitate the availability and distribution of study products, on-site monitoring or auditing, and other pharmaceutical services.
  • Participating in the presentation of research results, including publications.
  • Coordinating the negotiation of Clinical Trials Agreements (CTAs) and serve as the liaison with pharmaceutical companies (or other providers of investigational agents).
  • Notifying the recipient if NIAID will have the option to independently file an IND on investigational agents or an IDE on investigational devices evaluated in NIAID-supported clinical studies. NIAID will advise the investigators on the specific regulatory requirements for IND/IDE sponsorship. NIAID will provide current policies and procedures that govern the reporting of adverse events in NIAID-supported trials.
  • For studies in which NIAID is the IND or IDE sponsor, providing consultation on study treatment-related issues, including manufacturing, preparation, administration and availability of active dosage forms and placebo. When NIAID is not the regulatory sponsor, pharmaceutical support is provided on a case-by-case basis.
  • Ensuring the monitoring contractor will visit the clinical research sites periodically to review selected protocols, provide training on general protocol conduct, review internal QA/QC plans, and audit pharmacies for clinical trials under IND/IDE. When NIAID is not the regulatory sponsor, clinical monitoring support is provided on a case-by-case basis.
  • Providing a variety of training activities to help the Network ensure that consistent standards for protection of human subjects and clinical trial conduct and documentation are achieved across the NIAID-supported clinical trials Networks. Training areas include, but are not limited to, regulatory requirements, good clinical practice (GCP), adverse event reporting, human subject protections, informed consent, and NIAID and NIH policies and procedures.
  • Ensuring review and approval for all protocols prior to participant enrollment. If a protocol is disapproved, NIAID will not provide investigational products or permit expenditure of NIH funds for the proposed investigation. When a protocol is not initiated within twelve months of NIAID approval, re-review and approval by NIAID will be required.
  • Participating in developing and approving safety monitoring plans for clinical trials, especially those involving more than minimal risk. Serving on protocol safety review teams to monitor safety and efficacy of the intervention(s) for ongoing studies, including overseeing Serious Adverse Events with NIAID Medical Officers responsible for their disposition. Reviewing safety team composition prior to study initiation and supporting DSMBs for select trials.
  • NIAID reserves the right to terminate or curtail a clinical study. 
  • Additionally, an agency program official or ICO program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.

Areas of Joint Responsibility include:

  • Implementing, monitoring, and updating the clinical research priorities for the Network to ensure consistency and relevance.
  • Reviewing the Network's research activities and goals on an agreed upon schedule (but no less than once every year).
  • For protocol development, the LOC will assemble and manage protocol teams, NIAID staff and support contractors, as required, will participate in these teams.
  • An Executive Management Committee (EMC) will coordinate activities across the LOC, SDMC and LC and activities with affiliated CTU/CRSs. The EMC will be convened and chaired by the LOC and include the PDs/PIs of the LC and SDMC.
  • When NIAID is not the regulatory sponsor, pharmaceutical support is provided on a case-by-case basis.
  • When NIAID is not the regulatory sponsor, clinical monitoring support is provided on a case-by-case basis.
  • On an ongoing basis, the LOC, LC, SDMC, and NIAID staff will jointly evaluate the progress of clinical trials, including enrollment benchmarks, site and laboratory quality, and data quality. NIAID and NIAID contractors may audit applicable sites, SDMC, and laboratories to assess GCP and data quality and integrity.
  • NIAID, in conjunction with the EMC, will assess the performance of the LOC, LC, SDMC and CTUs/CRSs in an ongoing manner. The EMC will develop an evaluation plan with defined goals and measurable objectives linked to specific performance metrics and include remedial actions for sites failing to meet acceptable standards. 
  • Community Advisory Board (CAB) representatives will participate with NIAID and Network staff to evaluate and improve community engagement, strengthen communication within and across Networks, and identify training and support needs for both local and Network advisory boards.
  • NIAID may seek evaluation, advice and recommendation concerning ongoing and planned research activities of the Network from external advisors. Advisors will not include key personnel or collaborators of the key personnel of any of the recipients. Network investigators will participate in these evaluations and will provide written materials and oral presentations regarding the status of ongoing research activities, future (including proposed new research activities/investigators), and plans to curtail, discontinue and/or modify current research activities.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between recipients and NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened: a designee of the recipient, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and HHS regulation 45 CFR Part 16.

3. Data Management and Sharing

A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed. 

4. Reporting

When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement Section 8.4.1 Reporting. To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see Post-Award Monitoring and Reporting.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement Section 8.6 Closeout. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk - Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues.

Grants.gov Support Center - Questions regarding Grants.gov registration and services (e.g., Workspace, subscriptions).

Scientific/Research Contact(s)

National Institute of Allergy and Infectious Diseases (NIAID) 
Email: sciops@niaid.nih.gov

Office of AIDS Research (OAR)
Email: OARinfo@nih.gov

National Heart, Lung and Blood Institute (NHLBI)
Email: ctrisgrants@nih.gov
Subject: RFA-AI-28-001

National Institute on Aging (NIA)
Email: NIA-NOFO-Scientific@nih.gov
Please include the NOFO number in the subject line when emailing.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Email: nichd_mpidb_nofos@mail.nih.gov

National Institute of Dental and Craniofacial Research (NIDCR)
Email: NIDCR-Program@nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Division of Diabetes, Endocrinology and Metabolic Diseases
Email: NIDDK_DEM@nih.gov 
Division of Digestive Diseases and Nutrition
Email: NIDDK_DDN@nih.gov 
Division of Kidney, Urologic, and Hematologic Diseases
Email: NIDDK_KUH@nih.gov 

National Institute on Drug Abuse (NIDA)
Email: NIDAHIVProgram@mail.nih.gov

National Institute of Mental Health (NIMH)
Email: NIMH.DAR.inquiries@nih.gov

National Institute of Neurological Disorders and Stroke (NINDS)
Email: NINDSNeuroHIV@nih.gov 

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

National Institute of Allergy and Infectious Diseases (NIAID) 
Email: niaidfinancial-grantscontact@mail.nih.gov

Office of AIDS Research (OAR)
Email: OARinfo@nih.gov

National Heart, Lung and Blood Institute (NHLBI)
Email: NHLBIOGMInbox@nhlbi.nih.gov
Subject: RFA-AI-28-001

National Institute on Aging (NIA)
Email: NIA-NOFO-Grants@nih.gov
Please include the NOFO number in the subject line when emailing.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Email: nichdgrantsmanagement@mail.nih.gov

National Institute of Dental and Craniofacial Research (NIDCR)
Email: deeranotifications@nidcr.nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Email: NIDDKGMBManagementTeam@niddk.nih.gov 

National Institute on Drug Abuse (NIDA)
Email: nidagmbemail@nida.nih.gov

National Institute of Mental Health (NIMH)
Email: NIMHNOFOGrantsManagement@mail.nih.gov   

National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.